<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01758432</url>
  </required_header>
  <id_info>
    <org_study_id>12-502 Module 1</org_study_id>
    <nct_id>NCT01758432</nct_id>
  </id_info>
  <brief_title>Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)</brief_title>
  <official_title>A Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of
      several blood thinner drugs on laboratory tests. The study also is evaluating the blood
      levels of PRT064445 given at different doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, vehicle-controlled study to assess the safety, tolerability,
      pharmacokinetics, and pharmacodynamics of intravenously administered PRT064445 after dosing
      to steady state with one of four direct/indirect fXa inhibitors in healthy volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study has four modules with a total of 21 cohorts, each module was reported and submitted separately.
Module 1, NCT01758432 (54 subjects with 7cohorts including placebo); Module 2, NCT03578146 (48 subjects with 6 cohorts including placebo); Module 3, NCT03551730 (27 subjects with 4 cohorts including placebo); Module 4, NCT03551743 (28 subjects with 4 cohorts including placebo)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration</measure>
    <time_frame>Baseline to 2 minutes following the end of andexanet/placebo administration</time_frame>
    <description>Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration</measure>
    <time_frame>Baseline to 2 minutes following the end of andexanet/placebo administration</time_frame>
    <description>Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percent Change From Baseline in Unbound Apixaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration</measure>
    <time_frame>Baseline to 2 minutes following the end of andexanet/placebo administration</time_frame>
    <description>Unbound apixaban concentrations was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Unbound plasma concentrations for apixaban were determined by a rapid equilibrium dialysis method followed by Liquid Chromatography-Mass Spectometry assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Andexanet Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
    <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Cmax was taken directly from the raw data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Andexanet Time of Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
    <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Andexanet Total Volume of Distribution (Vss)</measure>
    <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
    <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )</measure>
    <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
    <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Andexanet Total Systemic Clearance (CL)</measure>
    <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
    <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach, calculated as Dose/AUC0-inf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Andexanet Apparent Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
    <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electro chemiluminescent assay. t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Module 1 (90 mg bolus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 mg PRT064445 given as a single IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 1 (210 mg bolus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>210 mg PRT064445 given as a single IV bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 1 (420 mg bolus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>420 mg PRT064445 given as a single IV bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg PRT064445 given as follows: 420 mg IV over ~14 minutes (~30 mg/min), followed by a continuous infusion of 180 mg (4 mg/min over 45 minutes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 1 (420 mg bolus + 180 mg bolus) 30mg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg PRT064445 given as follows: up to 420 mg IV over ~14 minutes (~30 mg/min), followed by a second bolus of 180 mg IV over ~6 minutes (~30 mg/min), 45 minutes after completion of the bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 1 (420 mg bolus + 480 mg infusion) 4mg/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg PRT064445 given as follows: 420 mg IV, followed by a continuous infusion of 480 mg (4 mg/min over 120 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 1 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PRT064445/Apixaban</intervention_name>
    <arm_group_label>Module 1 (210 mg bolus)</arm_group_label>
    <arm_group_label>Module 1 (420 mg bolus + 180 mg bolus) 30mg/min</arm_group_label>
    <arm_group_label>Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min</arm_group_label>
    <arm_group_label>Module 1 (420 mg bolus + 480 mg infusion) 4mg/min</arm_group_label>
    <arm_group_label>Module 1 (420 mg bolus)</arm_group_label>
    <arm_group_label>Module 1 (90 mg bolus)</arm_group_label>
    <other_name>Andexanet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo/Apixaban</intervention_name>
    <arm_group_label>Module 1 (210 mg bolus)</arm_group_label>
    <arm_group_label>Module 1 (420 mg bolus + 180 mg bolus) 30mg/min</arm_group_label>
    <arm_group_label>Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min</arm_group_label>
    <arm_group_label>Module 1 (420 mg bolus + 480 mg infusion) 4mg/min</arm_group_label>
    <arm_group_label>Module 1 (420 mg bolus)</arm_group_label>
    <arm_group_label>Module 1 (90 mg bolus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Module 1 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men or women between the ages of 18 and 45 years old

        Exclusion Criteria:

          -  History (including family history) or symptoms of, or risk factors for bleeding

          -  History (including family history) of or risk factors for a hypercoagulable or
             thrombotic condition

          -  Absolute/relative contraindication to anticoagulation or treatment with specific
             anticoagulants

          -  History of major surgery, severe trauma or bone fracture within 3 months prior to
             dosing; or planned surgery within 1 month after dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>December 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2013</study_first_posted>
  <results_first_submitted>May 30, 2018</results_first_submitted>
  <results_first_submitted_qc>July 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2018</results_first_posted>
  <disposition_first_submitted>September 19, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 19, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 27, 2017</disposition_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject recruitment occurred at investigative site in the US between November 2012 through October 2013</recruitment_details>
      <pre_assignment_details>Apixaban was administered orally at 5 mg twice daily for 6 days to steady-state in an open label fashion. Subjects were then randomized to receive study treatment (andexanet:placebo, 6:3) intravenously at different doses/dose regimens on Day 6, all bolus doses administered such that they ended at 3 hours after the last dose of apixaban.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Module 1 Placebo</title>
          <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
        </group>
        <group group_id="P2">
          <title>Module 1 ( 90 mg)</title>
          <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
        </group>
        <group group_id="P3">
          <title>Module 1 (210 mg)</title>
          <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
        </group>
        <group group_id="P4">
          <title>Module 1 (420 mg)</title>
          <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
        </group>
        <group group_id="P5">
          <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
          <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
        </group>
        <group group_id="P6">
          <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
          <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
        </group>
        <group group_id="P7">
          <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
          <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>54 subjects were enrolled in this study.</population>
      <group_list>
        <group group_id="B1">
          <title>Module 1 Placebo</title>
          <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
        </group>
        <group group_id="B2">
          <title>Module 1 ( 90 mg)</title>
          <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
        </group>
        <group group_id="B3">
          <title>Module 1 (210 mg)</title>
          <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
        </group>
        <group group_id="B4">
          <title>Module 1 (420 mg)</title>
          <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
        </group>
        <group group_id="B5">
          <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
          <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
        </group>
        <group group_id="B6">
          <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
          <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
        </group>
        <group group_id="B7">
          <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
          <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>54 subjects were enrolled in this study.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="7.69"/>
                    <measurement group_id="B2" value="33.7" spread="8.48"/>
                    <measurement group_id="B3" value="35.0" spread="7.32"/>
                    <measurement group_id="B4" value="33.8" spread="5.78"/>
                    <measurement group_id="B5" value="31.7" spread="9.50"/>
                    <measurement group_id="B6" value="32.5" spread="8.60"/>
                    <measurement group_id="B7" value="31.8" spread="6.97"/>
                    <measurement group_id="B8" value="33.2" spread="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration</title>
        <description>Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)</description>
        <time_frame>Baseline to 2 minutes following the end of andexanet/placebo administration</time_frame>
        <population>54 subjects who received andexanet or placebo were included in the pharmacodynamics (PD) analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Module 1 Placebo</title>
            <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Module 1 ( 90 mg)</title>
            <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O3">
            <title>Module 1 (210 mg)</title>
            <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O4">
            <title>Module 1 (420 mg)</title>
            <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O5">
            <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
          </group>
          <group group_id="O6">
            <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
            <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
          </group>
          <group group_id="O7">
            <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration</title>
          <description>Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)</description>
          <population>54 subjects who received andexanet or placebo were included in the pharmacodynamics (PD) analysis</population>
          <units>Percent change in anti-fXa activity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.06" spread="10.801"/>
                    <measurement group_id="O2" value="-67.79" spread="7.731"/>
                    <measurement group_id="O3" value="-78.51" spread="3.815"/>
                    <measurement group_id="O4" value="-95.04" spread="1.375"/>
                    <measurement group_id="O5" value="-94.03" spread="1.870"/>
                    <measurement group_id="O6" value="-93.07" spread="1.765"/>
                    <measurement group_id="O7" value="-92.82" spread="1.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-95.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-130.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-129.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-165.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-167.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-135.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration</title>
        <description>Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.</description>
        <time_frame>Baseline to 2 minutes following the end of andexanet/placebo administration</time_frame>
        <population>45 subjects who received andexanet or placebo were included in the PD analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Module 1 Placebo</title>
            <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Module 1 ( 90 mg)</title>
            <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O3">
            <title>Module 1 (210 mg)</title>
            <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O4">
            <title>Module 1 (420 mg)</title>
            <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O5">
            <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
          </group>
          <group group_id="O6">
            <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
            <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
          </group>
          <group group_id="O7">
            <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration</title>
          <description>Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.</description>
          <population>45 subjects who received andexanet or placebo were included in the PD analysis</population>
          <units>Percent change in thrombin generation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.11" spread="36.871"/>
                    <measurement group_id="O2" value="76.58" spread="47.729"/>
                    <measurement group_id="O3" value="137.50" spread="67.528"/>
                    <measurement group_id="O4" value="120.95" spread="91.301"/>
                    <measurement group_id="O5" value="222.56" spread="95.671"/>
                    <measurement group_id="O6" value="196.29" spread="65.406"/>
                    <measurement group_id="O7" value="191.77" spread="122.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>85559.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>105508.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>182753.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>193684.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>178055</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>169709.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percent Change From Baseline in Unbound Apixaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration</title>
        <description>Unbound apixaban concentrations was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Unbound plasma concentrations for apixaban were determined by a rapid equilibrium dialysis method followed by Liquid Chromatography-Mass Spectometry assay.</description>
        <time_frame>Baseline to 2 minutes following the end of andexanet/placebo administration</time_frame>
        <population>54 subjects who received apixaban were included in the apixaban pharmacokinetics (PK) analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Module 1 Placebo</title>
            <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Module 1 ( 90 mg)</title>
            <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O3">
            <title>Module 1 (210 mg)</title>
            <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O4">
            <title>Module 1 (420 mg)</title>
            <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O5">
            <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
          </group>
          <group group_id="O6">
            <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
            <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
          </group>
          <group group_id="O7">
            <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percent Change From Baseline in Unbound Apixaban Plasma Concentration at 2 Mins Following Andexanet/Placebo Administration</title>
          <description>Unbound apixaban concentrations was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Unbound plasma concentrations for apixaban were determined by a rapid equilibrium dialysis method followed by Liquid Chromatography-Mass Spectometry assay.</description>
          <population>54 subjects who received apixaban were included in the apixaban pharmacokinetics (PK) analysis</population>
          <units>% change in unbound apixaban concentrat.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="14"/>
                    <measurement group_id="O2" value="-51" spread="12"/>
                    <measurement group_id="O3" value="-54" spread="7"/>
                    <measurement group_id="O4" value="-72" spread="7"/>
                    <measurement group_id="O5" value="-79" spread="6"/>
                    <measurement group_id="O6" value="-89" spread="3"/>
                    <measurement group_id="O7" value="-84" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-4.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-4.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-6.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-6.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-7.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Means (Difference)</param_type>
            <param_value>-6.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Andexanet Maximum Observed Plasma Concentration (Cmax)</title>
        <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Cmax was taken directly from the raw data.</description>
        <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
        <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Module 1 Placebo</title>
            <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Module 1 ( 90 mg)</title>
            <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O3">
            <title>Module 1 (210 mg)</title>
            <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O4">
            <title>Module 1 (420 mg)</title>
            <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O5">
            <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
          </group>
          <group group_id="O6">
            <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
            <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
          </group>
          <group group_id="O7">
            <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
          </group>
        </group_list>
        <measure>
          <title>Andexanet Maximum Observed Plasma Concentration (Cmax)</title>
          <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Cmax was taken directly from the raw data.</description>
          <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Andexanet not administered (placebo group)</measurement>
                    <measurement group_id="O2" value="21200" spread="2400"/>
                    <measurement group_id="O3" value="42800" spread="5620"/>
                    <measurement group_id="O4" value="81400" spread="10900"/>
                    <measurement group_id="O5" value="93300" spread="18400"/>
                    <measurement group_id="O6" value="88000" spread="9010"/>
                    <measurement group_id="O7" value="90800" spread="29600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Andexanet Time of Maximum Observed Plasma Concentration (Tmax)</title>
        <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.</description>
        <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
        <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Module 1 Placebo</title>
            <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Module 1 ( 90 mg)</title>
            <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O3">
            <title>Module 1 (210 mg)</title>
            <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O4">
            <title>Module 1 (420 mg)</title>
            <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O5">
            <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
          </group>
          <group group_id="O6">
            <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
            <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
          </group>
          <group group_id="O7">
            <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
          </group>
        </group_list>
        <measure>
          <title>Andexanet Time of Maximum Observed Plasma Concentration (Tmax)</title>
          <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.</description>
          <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Andexanet was not administered (placebo group)</measurement>
                    <measurement group_id="O2" value="0.07" lower_limit="0.07" upper_limit="0.08"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.14" upper_limit="0.30"/>
                    <measurement group_id="O4" value="0.27" lower_limit="0.26" upper_limit="0.29"/>
                    <measurement group_id="O5" value="0.43" lower_limit="0.25" upper_limit="0.52"/>
                    <measurement group_id="O6" value="0.27" lower_limit="0.26" upper_limit="0.31"/>
                    <measurement group_id="O7" value="0.28" lower_limit="0.272" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Andexanet Total Volume of Distribution (Vss)</title>
        <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.</description>
        <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
        <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Module 1 Placebo</title>
            <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Module 1 ( 90 mg)</title>
            <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O3">
            <title>Module 1 (210 mg)</title>
            <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O4">
            <title>Module 1 (420 mg)</title>
            <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O5">
            <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
          </group>
          <group group_id="O6">
            <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
            <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
          </group>
          <group group_id="O7">
            <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
          </group>
        </group_list>
        <measure>
          <title>Andexanet Total Volume of Distribution (Vss)</title>
          <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.</description>
          <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Andexanet not administered (placebo group)</measurement>
                    <measurement group_id="O2" value="6.97" spread="1.42"/>
                    <measurement group_id="O3" value="6.18" spread="1.31"/>
                    <measurement group_id="O4" value="6.26" spread="0.742"/>
                    <measurement group_id="O5" value="5.11" spread="1.64"/>
                    <measurement group_id="O6" value="NA" spread="NA">Vss calculations do not take into account the 45 minute intervals between doses.</measurement>
                    <measurement group_id="O7" value="4.01" spread="0.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )</title>
        <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach</description>
        <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
        <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Module 1 Placebo</title>
            <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Module 1 ( 90 mg)</title>
            <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O3">
            <title>Module 1 (210 mg)</title>
            <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O4">
            <title>Module 1 (420 mg)</title>
            <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O5">
            <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
          </group>
          <group group_id="O6">
            <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
            <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
          </group>
          <group group_id="O7">
            <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
          </group>
        </group_list>
        <measure>
          <title>Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )</title>
          <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach</description>
          <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Andexanet was not administered (placebo group)</measurement>
                    <measurement group_id="O2" value="23400" spread="3460"/>
                    <measurement group_id="O3" value="49200" spread="3960"/>
                    <measurement group_id="O4" value="93500" spread="15500"/>
                    <measurement group_id="O5" value="131000" spread="20500"/>
                    <measurement group_id="O6" value="155000" spread="16200"/>
                    <measurement group_id="O7" value="213000" spread="33900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Andexanet Total Systemic Clearance (CL)</title>
        <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach, calculated as Dose/AUC0-inf</description>
        <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
        <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Module 1 Placebo</title>
            <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Module 1 ( 90 mg)</title>
            <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O3">
            <title>Module 1 (210 mg)</title>
            <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O4">
            <title>Module 1 (420 mg)</title>
            <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O5">
            <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
          </group>
          <group group_id="O6">
            <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
            <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
          </group>
          <group group_id="O7">
            <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
          </group>
        </group_list>
        <measure>
          <title>Andexanet Total Systemic Clearance (CL)</title>
          <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach, calculated as Dose/AUC0-inf</description>
          <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Andexanet not administered (placebo group)</measurement>
                    <measurement group_id="O2" value="3.93" spread="0.634"/>
                    <measurement group_id="O3" value="4.29" spread="0.331"/>
                    <measurement group_id="O4" value="4.60" spread="0.814"/>
                    <measurement group_id="O5" value="4.70" spread="0.887"/>
                    <measurement group_id="O6" value="NA" spread="NA">Not determined as CL</measurement>
                    <measurement group_id="O7" value="4.30" spread="0.608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Andexanet Apparent Terminal Elimination Half-life (t1/2)</title>
        <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electro chemiluminescent assay. t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.</description>
        <time_frame>Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.</time_frame>
        <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Module 1 Placebo</title>
            <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
          </group>
          <group group_id="O2">
            <title>Module 1 ( 90 mg)</title>
            <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O3">
            <title>Module 1 (210 mg)</title>
            <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O4">
            <title>Module 1 (420 mg)</title>
            <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
          </group>
          <group group_id="O5">
            <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
          </group>
          <group group_id="O6">
            <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
            <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
          </group>
          <group group_id="O7">
            <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
            <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
          </group>
        </group_list>
        <measure>
          <title>Andexanet Apparent Terminal Elimination Half-life (t1/2)</title>
          <description>Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electro chemiluminescent assay. t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.</description>
          <population>36 subjects who received andexanet were included in the andexanet PK analysis</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Andexanet was not administered (placebo group)</measurement>
                    <measurement group_id="O2" value="5.51" spread="0.84"/>
                    <measurement group_id="O3" value="5.12" spread="1.66"/>
                    <measurement group_id="O4" value="5.02" spread="2.02"/>
                    <measurement group_id="O5" value="4.35" spread="1.40"/>
                    <measurement group_id="O6" value="5.79" spread="2.00"/>
                    <measurement group_id="O7" value="6.45" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>~7 weeks</time_frame>
      <desc>Only subjects who received at least one dose of study drug were included in the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Module 1 Placebo</title>
          <description>Placebo was administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.</description>
        </group>
        <group group_id="E2">
          <title>Module 1 ( 90 mg)</title>
          <description>90 mg andexanet IV bolus administered over 3 minutes (~30 mg/min)</description>
        </group>
        <group group_id="E3">
          <title>Module 1 (210 mg)</title>
          <description>210 mg andexanet IV bolus administered over 10 minutes (~30 mg/min) 420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
        </group>
        <group group_id="E4">
          <title>Module 1 (420 mg)</title>
          <description>420 mg andexanet IV bolus administered over 15 minutes (~30 mg/min)</description>
        </group>
        <group group_id="E5">
          <title>Module 1 (420 mg Bolus + 180 mg Infusion)</title>
          <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 180 mg continuous IV infusion (4 mg/min over 45 minutes) [total 600 mg]</description>
        </group>
        <group group_id="E6">
          <title>Module 1 (420 mg Bolus + 180 mg Bolus)</title>
          <description>420 mg andexanet/placebo IV bolus administered over ~14 minutes (~30 mg/min) followed after 45 minutes by a second bolus of 180 mg over~ 6 minutes (~30 mg/min) [total 600 mg]</description>
        </group>
        <group group_id="E7">
          <title>Module 1 (420 mg Bolus + 480 mg Infusion)</title>
          <description>420 mg andexanet IV bolus administered over ~14 minutes (~30 mg/min) followed immediately by a 480 mg continuous IV infusion (4 mg/min over 2 hours) [total 900 mg]</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus generalized</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Conducted in healthy volunteers at Clinical Research Organization</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Development</name_or_title>
      <organization>Portola Pharmaceuticals, Inc.</organization>
      <phone>650-246-7000</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

